acetaminophen has been researched along with Cancer of Endometrium in 10 studies
Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.
paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " More large scale prospective cohort studies are warranted to confirm our findings and carry out the dose-response analysis of aforementioned association." | 2.55 | Use of acetaminophen and risk of endometrial cancer: evidence from observational studies. ( Ding, YY; Han, ZK; Hong, T; Li, HX; Verma, S; Yao, P; Zhu, YQ, 2017) |
| " There was a significant inverse dose-response (p-trend <0." | 2.49 | Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis. ( Nagle, CM; Neill, AS; Obermair, A; Protani, MM; Spurdle, AB; Webb, PM, 2013) |
| "We enrolled endometrial cancer patients undergoing open abdominal hysterectomy with lymphadenectomy by the same surgeon." | 1.40 | Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy. ( Jennings, PW; Santoso, JT; Ulm, MA; Wan, JY, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (30.00) | 29.6817 |
| 2010's | 7 (70.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ding, YY | 1 |
| Yao, P | 1 |
| Verma, S | 1 |
| Han, ZK | 1 |
| Hong, T | 1 |
| Zhu, YQ | 1 |
| Li, HX | 1 |
| Webb, PM | 2 |
| Na, R | 1 |
| Weiderpass, E | 1 |
| Adami, HO | 1 |
| Anderson, KE | 1 |
| Bertrand, KA | 1 |
| Botteri, E | 1 |
| Brasky, TM | 1 |
| Brinton, LA | 1 |
| Chen, C | 1 |
| Doherty, JA | 1 |
| Lu, L | 1 |
| McCann, SE | 1 |
| Moysich, KB | 2 |
| Olson, S | 1 |
| Petruzella, S | 1 |
| Palmer, JR | 1 |
| Prizment, AE | 1 |
| Schairer, C | 1 |
| Setiawan, VW | 1 |
| Spurdle, AB | 2 |
| Trabert, B | 1 |
| Wentzensen, N | 1 |
| Wilkens, L | 1 |
| Yang, HP | 1 |
| Yu, H | 1 |
| Risch, HA | 1 |
| Jordan, SJ | 1 |
| Santoso, JT | 1 |
| Ulm, MA | 1 |
| Jennings, PW | 1 |
| Wan, JY | 1 |
| Abitbol, J | 1 |
| Cohn, R | 1 |
| Hunter, S | 1 |
| Rombaldi, M | 1 |
| Cohen, E | 1 |
| Kessous, R | 1 |
| Large, N | 1 |
| Reiss, A | 1 |
| Lau, S | 1 |
| Salvador, S | 1 |
| Gotlieb, WH | 1 |
| Samulak, D | 1 |
| Michalska, M | 1 |
| Gaca, M | 1 |
| Wilczak, M | 1 |
| Mojs, E | 1 |
| Chuchracki, M | 1 |
| Guzel, AI | 1 |
| Kuyumcuoglu, U | 1 |
| Celik, Y | 1 |
| Neill, AS | 1 |
| Nagle, CM | 1 |
| Protani, MM | 1 |
| Obermair, A | 1 |
| Dowdy, J | 1 |
| Brower, S | 1 |
| Miller, MR | 1 |
| Baker, JA | 1 |
| Rodabaugh, KJ | 1 |
| Villella, JA | 1 |
| Viswanathan, AN | 1 |
| Feskanich, D | 1 |
| Schernhammer, ES | 1 |
| Hankinson, SE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multimodal Pain Management for Cesarean Delivery: A Randomized Control Trial[NCT02922985] | Phase 4 | 120 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
This is the Apgar score of the newborn collected at 5 minutes. Range is from 0-10, with the higher scores meaning a better outcome. (NCT02922985)
Timeframe: 5 minutes after birth
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 9 |
| Multimodal Pain Regimen Group | 9 |
Time to discharge from hospital, measured in hours (NCT02922985)
Timeframe: From time of hospital admission to time of discharge home up to 168 hours.
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 50.2 |
| Multimodal Pain Regimen Group | 50 |
neonate receipt of oxygen by nasal cannula or mechanical ventilation (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 0 |
| Multimodal Pain Regimen Group | 4 |
Rate of admission to the neonatal intensive care unit (NCT02922985)
Timeframe: after birth and before hospital discharge
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo Control Group | 2 |
| Multimodal Pain Regimen Group | 6 |
Number of opioid pain tablets remaining on post-operative day #7 from hospital discharge as reported by patients (NCT02922985)
Timeframe: 7 days post delivery
| Intervention | Tablets (Median) |
|---|---|
| Placebo Control Group | 18 |
| Multimodal Pain Regimen Group | 19 |
Pain Score at 24 Hours Post Operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 24 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 5 |
| Multimodal Pain Regimen Group | 6 |
Pain Score at 48 Hours Post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 48 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 4 |
| Multimodal Pain Regimen Group | 3 |
Pain score at 6-12 hours post-operatively, expressed on a pain scale from 0-10 with the higher score meaning worse pain (outcome). (NCT02922985)
Timeframe: 6-12 hours post-operatively
| Intervention | score on a scale (Median) |
|---|---|
| Placebo Control Group | 6 |
| Multimodal Pain Regimen Group | 6 |
Time, in hours, to first administration of opioid pain medication post operatively (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | hours (Median) |
|---|---|
| Placebo Control Group | 6.05 |
| Multimodal Pain Regimen Group | 6.35 |
Every opioid intake by the patient in the first 48 hours after CD will be recorded and quantified in morphine milligram equivalents (NCT02922985)
Timeframe: 48 hours post cesarean delivery
| Intervention | morphine milligram equivalents (Median) |
|---|---|
| Placebo Control Group | 42 |
| Multimodal Pain Regimen Group | 49.5 |
2 reviews available for acetaminophen and Cancer of Endometrium
| Article | Year |
|---|---|
Use of acetaminophen and risk of endometrial cancer: evidence from observational studies.
Topics: Acetaminophen; Case-Control Studies; Databases, Factual; Endometrial Neoplasms; Female; Humans; Obse | 2017 |
Aspirin, nonsteroidal anti-inflammatory drugs, paracetamol and risk of endometrial cancer: a case-control study, systematic review and meta-analysis.
Topics: Acetaminophen; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Case-Control Studies; Co | 2013 |
2 trials available for acetaminophen and Cancer of Endometrium
| Article | Year |
|---|---|
Efficiency of postoperative pain management after gynecologic oncological surgeries with the use of morphine + acetaminophen + ketoprofen versus morphine + metamizol + ketoprofen.
Topics: Acetaminophen; Analgesics; Carcinoma; Dipyrone; Drug Therapy, Combination; Endometrial Neoplasms; Fe | 2011 |
Comparative effect of lornoxicam and paracetamol in pain relief in endometrial sampling.
Topics: Acetaminophen; Adult; Double-Blind Method; Endometrial Neoplasms; Female; Humans; Middle Aged; Pain | 2012 |
6 other studies available for acetaminophen and Cancer of Endometrium
| Article | Year |
|---|---|
Use of aspirin, other nonsteroidal anti-inflammatory drugs and acetaminophen and risk of endometrial cancer: the Epidemiology of Endometrial Cancer Consortium.
Topics: Acetaminophen; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Cont | 2019 |
Multimodal pain control is associated with reduced hospital stay following open abdominal hysterectomy.
Topics: Acetaminophen; Adolescent; Adult; Aged; Aged, 80 and over; Amines; Analgesics; Bupivacaine; Cohort S | 2014 |
Minimizing pain medication use and its associated costs following robotic surgery.
Topics: Acetaminophen; Aged; Analgesia, Patient-Controlled; Analgesics; Anti-Inflammatory Agents, Non-Steroi | 2017 |
Acetaminophen exhibits weak antiestrogenic activity in human endometrial adenocarcinoma (Ishikawa) cells.
Topics: Acetaminophen; Adenocarcinoma; Alkaline Phosphatase; Analgesics, Non-Narcotic; Dose-Response Relatio | 2003 |
Regular analgesic use and risk of endometrial cancer.
Topics: Acetaminophen; Analgesics; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Case-C | 2005 |
Aspirin, NSAID, and acetaminophen use and the risk of endometrial cancer.
Topics: Acetaminophen; Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cohort Stud | 2008 |